Please wait a moment . . .
In early 2020, as the COVID-19 pandemic reshaped our world, Medialis Ltd recognised the urgent need for a disease-specific quality of life (QoL) instrument for long COVID patients. This, led to the development of the PAC-19QoL. Rapid Development Timeline: We received ethical approval in October 2020 and initiated the development of the PAC-19QoL on November...
Medialis Ltd is proud to present our latest publication: “Real-world service cost’s for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis” in Current Medical Research & Opinions Real-world Evidence section Key Highlights: Innovative Use of Neutral Theory & Jandhyala Method: We leveraged these advanced methodologies to develop the nAMD Service Non-Drug...
Payors are crucial in the adoption of new medicines, especially in markets that prioritise cost-effectiveness. While HTA agencies and payors often prioritise clinical trial data, there are significant evidence gaps that these trials do not cover. Real-World Evidence (RWE) becomes crucial in this scenario, offering additional context and data to support reimbursement applications. Submitting incomplete...
In today’s rapidly evolving healthcare landscape, how confident are you that your organisation is generating comprehensive and accurate evidence? At Medialis Ltd, we specialise in providing robust real-world evidence that empowers decision-making and drives better outcomes by enabling more patients to receive new medicines sooner. Medialis Ltd can help you develop Quality of Life...
Introduction Low rates of inclusion of real-world evidence (RWE) during regulation may arise from lack of clarity and consensus on its definition. A conceptually mature definition of RWE may have pragmatic utility, increasing its inclusion during regulation. The aim was to develop a definition of RWE to promote inclusion in regulatory submissions and assess...
We Medialis Ltd are pleased to share with you the third of a series of updates on the principles underlying our work, the four pillars of our medical #thirty22 #realworldevidence strategy. Pillar 3 of our strategy focuses on the application of the #multiplestakeholderapproach to #realworldevidence generation for #clinicalstudies. Our research showed that stakeholder groups have...
We @Medialis Ltd are pleased to share the first of a series of updates on the #medicalaffairs principles underlying our work, the four pillars of our medical #thirty22RWEstrategy in the #pharmaceuticalindustry, #rarediseases and #orphandrugs. Pillar 1 of our strategy focuses on the application of #Neutraltheory to #constructmeasurement problems in #clinicaltrials and #clinicalstudies. #Neutral theory allows...
Background The novel coronavirus (SARS-CoV-2) has led to a global pandemic, resulting in a disease termed COVID-19, which commonly presents in adults as a typical infection of the upper respiratory tract. Although the disease is often acute, one in ten patients can continue to be affected for weeks or months, resulting in a state called...
We Medialis Ltd are pleased to announce our latest workshop, How to Generate RWE for Regulators, Payors, Prescribers and Patients, launching online in 2022. As part of this value-packed #traininganddevelopment event, you will discover : – How to optimise the adoption of your new #medicine by generating high quality #RWE tailored to #stakeholderengagement needs –...